Appaiahgari Mohan Babu, Vrati Sudhanshu
Translational Health Science and Technology Institute, Vaccine and Infectious Disease Research Centre , 496, Udyog Vihar Phase III, Gurgaon 122 016 , India +91 124 2876301 ; +91 124 2876402 ;
Expert Opin Biol Ther. 2015 Mar;15(3):337-51. doi: 10.1517/14712598.2015.993374. Epub 2014 Dec 22.
Adenoviruses (Ads) have attracted researchers from across the disciplines for several reasons. Their ability to recombine with and express the heterologous genes encouraged their development as gene/vaccine delivery vectors. Preclinical and clinical trials using these vectors have shown significant promise for their future development while highlighting certain limitations.
Ad vector development, clinical application of these vectors in gene therapy and vaccine development, and promises that these vectors offered for future development are discussed. Also, various factors affecting their in vivo efficacy as well as the strategies being pursued to overcome these obstacles are described.
Decades of efforts have resulted in understanding various aspects of human Ad 5 biology as well as the in vivo behavior of vectors derived from this serotype. While this vector has shown great potential, some of the limitations highlighted in recent studies have reinforced the quest for an ideal vector derived from novel Ads. Combinatorial approaches to address the various limitations of the existing vectors must be pursued to develop novel vectors with enhanced clinical potential.
腺病毒（Ads）因其多种原因吸引了来自各个学科的研究人员。它们与异源基因重组并表达的能力促进了其作为基因/疫苗递送载体的发展。使用这些载体的临床前和临床试验已显示出其未来发展的巨大潜力，同时也凸显了某些局限性。
讨论了腺病毒载体的发展、这些载体在基因治疗和疫苗开发中的临床应用，以及这些载体为未来发展带来的前景。此外，还描述了影响其体内疗效的各种因素以及为克服这些障碍所采取的策略。
数十年的努力已使人们对人5型腺病毒生物学的各个方面以及源自该血清型的载体的体内行为有了了解。虽然这种载体已显示出巨大潜力，但近期研究中突出的一些局限性强化了对源自新型腺病毒的理想载体的探索。必须采用组合方法来解决现有载体的各种局限性，以开发具有更高临床潜力的新型载体。
